The deep imaging capability and optical absorption contrast offered by photoacoustic imaging promote the use of this technology in clinical applications. By exploiting the optical absorption properties of endogenous chromophores such as hemoglobin and lipid, molecular information at a depth of a few centimeters can be unveiled. This information shows promise to reveal lesions indicating early stage of various human diseases, such as cancer and atherosclerosis. In addition, the use of exogenous contrast agents can further extend the capability of photoacoustic imaging in clinical diagnosis and treatment. In this review, the current state of the art and applications of photoacoustic molecular probes will be critically reviewed, as well as some spearheading translational efforts that have taken place over the past 5 years. Some of the most critical barriers to clinical translation of this novel technology will be discussed, and some thoughts will be given on future endeavors and pathways. Phot oacoustic imaging (PAI) has been shown to be a promising medical imaging technology. This technique is based on the photoacoustic effect by which ultrasound waves are generated because of light absorption in the tissue's chromophores. Therefore, endogenous chromophores and exogenous contrast agents can be used to provide excellent contrast in photoacoustic molecular imaging. In a previous review, applications of photoacoustic molecular imaging of cancer in vivo using endogenous chromophores and exogenous contrast agents were discussed (1). Over the past few years, the technology has been extensively applied to numerous human diseases. Diagnosis of various diseases at an early stage through screening, as well as monitoring of treatment, is possible using PAI with endogenous chromophores. In addition, novel approaches to the use of photoacoustic contrast agents have been significantly investigated to enhance contrast, targeting, and therapeutics over traditional probes for molecular theranostics. This review focuses on recent research on photoacoustic molecular imaging exploiting endogenous chromophores and exogenous contrast agents.
Phot oacoustic imaging (PAI) has been shown to be a promising medical imaging technology. This technique is based on the photoacoustic effect by which ultrasound waves are generated because of light absorption in the tissue's chromophores. Therefore, endogenous chromophores and exogenous contrast agents can be used to provide excellent contrast in photoacoustic molecular imaging. In a previous review, applications of photoacoustic molecular imaging of cancer in vivo using endogenous chromophores and exogenous contrast agents were discussed (1) . Over the past few years, the technology has been extensively applied to numerous human diseases. Diagnosis of various diseases at an early stage through screening, as well as monitoring of treatment, is possible using PAI with endogenous chromophores. In addition, novel approaches to the use of photoacoustic contrast agents have been significantly investigated to enhance contrast, targeting, and therapeutics over traditional probes for molecular theranostics. This review focuses on recent research on photoacoustic molecular imaging exploiting endogenous chromophores and exogenous contrast agents.
PAI WITH ENDOGENOUS CHROMOPHORES
Endogenous chromophores with significantly different absorption spectra produce high endogenous contrast in PAI. Specific wavelengths can be selected to obtain maximum contrast. Furthermore, PAI can take advantage of near-infrared light at wavelengths in the range 650-1,200 nm for deep imaging. Angiogenesis, the formation of new blood vessels, is one of the basic hallmarks of various diseases such as cancer (2) . Therefore, cancer can be revealed with PAI of hemoglobin, one of the major chromophores. As an example, Figure 1 shows maximum-intensity-projection photoacoustic images of a 40-y-old woman's breasts after elimination of superficial blood vessels from the images. In this section, we focus on PAI uses that are close to becoming clinically applicable.
Breast Cancer
Breast cancer is the leading cause of cancer death in women globally. In 2012, 0.5 million women worldwide died of breast cancer, accounting for 15% of all cancer deaths in women (3) . Because angiogenesis is the marker of cancer, imaging with light at wavelengths that are mainly absorbed by the chromophores deoxy-and oxyhemoglobin can be exploited to distinguish between malignant and normal breast tissue and to monitor therapy (2).
Heijblom et al. used the Twente photoacoustic mammoscope to investigate breast cancer lesions in 31 patients (4), with 32 of 33 malignancies being visualized with high imaging contrast. On average, the lesions were seen with higher contrast on photoacoustic images than on x-ray mammography. Moreover, photoacoustic contrast was independent of mammographic breast density, whereas with x-ray mammography there was a significant decrease in contrast in the low-density group compared with the highdensity group.
A new photoacoustic mammography system offering remarkably more morphologic and structural details of blood vessels than can be seen with MRI was reported by Toi et al. (5) . Additionally, combining these techniques allows visualization of both the tumor mass and its related vasculature in one image, shown in their study on 22 malignancies. By using 2 wavelengths (755 and 795 nm) for imaging, the investigators could estimate the oxygen saturation of hemoglobin (sO 2 ). This information would give insight on the tumor microenvironment and facilitate monitoring of treatment such as chemotherapy and anti-HER2 treatment.
Crohn Disease
Crohn disease is an inflammatory bowel disease often leading to severe injuries or even death. The inflammation can be revealed by measuring hemoglobin and oxygenated hemoglobin content in the intestinal wall. Knieling et al. proposed a noninvasive approach to distinguish active and nonactive Crohn disease by determining the hemoglobin level in the intestinal wall with multispectral photoacoustic tomography (6) . They performed multispectral photoacoustic tomography on 108 Crohn disease patients with 6 wavelengths and extracted total oxygenated and deoxygenated hemoglobin and sO 2 in the intestinal wall. They found significant differences between active and nonactive Crohn disease for all multispectral photoacoustic tomography values excluding sO 2 when using endoscopy and histologic characteristics as references.
Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes progressive destruction of affected joints leading to severe disability and even death. Conventional radiography is the technique currently used for detection of joint damage. However, radiography cannot detect the disease in the early stage (7) . PAI, therefore, can be exploited because hypervascularization and angiogenesis are the hallmarks of the early stage.
van den Berg et al. observed large differences in photoacoustic images of inflamed, healthy, and noninflamed proximal interphalangeal finger joints (8) . Figure 2 represents their setup and some results. They used a handheld probe with cost-efficient integrated diode lasers ( Fig. 2A ) and a compact PAI system for imaging finger joints (Fig.  2B) . A larger number of high-photoacoustic pixels (indicating the presence of blood) was observed in the photoacoustic images of inflamed joints (Fig. 2C ) than in the images of noninflamed joints (Fig. 2D) . Figure 2E shows their quantification study on the finger joints of 7 healthy volunteers and 10 rheumatoid arthritis patients. It appeared that inflamed (8, 9) . With a photoacoustic-ultrasound dual-imaging system, they could evaluate the increased hemoglobin content, exposing hyperemia, in arthritic joints over normal joints. In addition, they performed PAI using 2 wavelengths (576 and 584 nm) to quantify sO 2 in each joint. Their results showed a recognizable decrease in sO 2 , representing hypoxia, in arthritic joints compared with normal joints. Another report from this group showed the potential of using PAI to monitor the treatment process of arthritic joints (10).
Psoriasis
Psoriasis is an incurable inflammatory skin disease. Many noninvasive imaging techniques have been proposed to facilitate the study of psoriatic skins. However, they are limited by the imaging depth, contrast, or resolution (11, 12) . Aguirre et al. presented an ultra-broadband raster-scan photoacoustic mesoscopy system that could visualize the skin up to subdermis layer with a lateral resolution of about 20 mm (12). Ultra-broadband raster-scan photoacoustic mesoscopy implemented in a hand-held probe allowed them to study vascular and melanin structures in healthy and psoriatic patients, reflecting the clinical potential of the technique. Images from 6 psoriasis patients showed that the blood volume per skin surface, the fractal number of the vasculature, and the epidermal thickness were all higher in psoriatic skin than in healthy skin. In addition, developing ultra-fast lasers will enable multispectral measurements for ultra-broadband raster-scan photoacoustic mesoscopy that could enhance the skin examination by showing oxygenation and differentiation of the melanin contributions.
Prostate Cancer
Prostate cancer is the second most common male cancer, close behind lung cancer. In 2012, 1.1 million men had prostate cancer, representing 15% of all cancers in men during that year (3) . Removing the tumor without affecting the nearby neurovascular bundles required for sexual potency is the goal of radical prostatectomy. Success strongly depends on the surgeon's experience. In addition, screening for angiogenesis can be used to detect the tumor. For those purposes, hemoglobin was exploited as an endogenous chromophore by Horiguchi et al. (13) and Ishihara et al. with a PAI system combining photoacoustic and ultrasound imaging (14) . They were able to visualize the periprostatic microvasculature and a photoacoustic signal pattern indicating cancer. Their handheld probe with real-time imaging shows promise for assisting surgeons during radical prostatectomy.
Atherosclerotic Plaque
Vulnerable atherosclerotic plaque can lead to cardiovascular events, which are the leading cause of death globally (15) (16, 17) . They showed that these types of lipids have slightly different absorption spectra. Using a combined intravascular photoacoustic and ultrasound imaging system, with multiple wavelengths near 1,200 and 1,700 nm, they were able to distinguish periadventitial lipids and lipids in the plaque in human coronary arteries ex vivo. Catheter-based intravascular photoacoustic-intravascular ultrasound imaging systems can display images in real time, enhancing this technique's advantages for clinical applications (18) .
PHOTOACOUSTIC MOLECULAR IMAGING WITH EXOGENOUS CONTRAST AGENTS
Exogenous photoacoustic contrast agents have been extensively studied in the past few years to provide molecular information on diseases with enhanced contrast (1). Clinically approved fluorescent agents with low quantum yields such as sodium fluorescein, IRDye 800CW, methylene blue, and indocyanine green have been repurposed for contrast-enhanced PAI in preclinical studies, but only one clinical study has been reported so far in which methylene blue was used to photoacoustically detect sentinel lymph node in breast cancer (19) . Besides these dyes, there have been continuous collective efforts to improve overall photoacoustic contrast, imaging depth, and specificity to the biomarkers, which would extend the capability of PAI for better diagnosis and treatments and might foster clinical translation. In this section, recent approaches to developing photoacoustic theranostic agents will be discussed.
Exogenous Contrast Agents for Contrast-Enhanced, Deep-Tissue, and Multimodal PAI Although ultrasonically triggered phase-transition droplets as ultrasound contrast agent were discussed in the previous review, in this review optically triggered phase transition droplets as a promising photoacoustic contrast agent with superior efficiency are discussed (1, 20, 21) . Most photoacoustic contrast agents generate signals through thermal expansion, which is known to have relatively low photoacoustic conversion efficiency (21) . The perfluorocarbon family is often used to form the droplet core for its low bulk boiling temperature, such as perfluoropentane (boiling point, 29°C). Once the liquid core is encapsulated by a thin layer of lipid, polymer, or protein, the vaporization temperature increases because of the increased Laplace pressure so that it maintains the liquid at physiologic temperature (22) . These shelled droplets contain chromophores that increase temperature locally on light absorption (Figs. 3A and 3B ). The resulting rapid volume expansion of the shelledconstruct generates strong signals, providing significantly enhanced contrast compared with thermal expansion-based photoacoustic signals (Figs. 3B and 3C) (20, 22) . With therapeutics inside and targeting molecules on the surface, these droplets can serve as disease-specific theranostic molecular probes (Fig. 3A) . Furthermore, activated droplets that turn into gas bubbles can be used for contrast-enhanced ultrasound imaging. In this way, these droplets serve as dual-mode contrast agents for combined photoacoustic and ultrasound imaging (20, 23) . Recently, some efforts were initiated to unveil underlying physics of optically triggered droplets using theoretic models and experimental observations. These observations and findings so far may lead to the design of droplets with optimal parameters for in vivo use, which include a balance between photoacoustic conversion efficiency and safety, and may provide a strong motivation to further develop droplets and evaluate them for use as a theranostic nanoplatform conjugated with targeting and therapeutic molecules (Fig. 3D ) (20, 22, 24) .
Relatively deep imaging is a key advantage of PAI over conventional optical imaging technologies. To maximize PAI depth, Zhou et al. suggested the use of phosphorus phthalocyanine with a long wavelength absorption beyond 1,000 nm to reduce light scattering, enhancing imaging depth. They successfully demonstrated PAI at depths of 11 cm in chicken breast tissue and 5 cm through human arms (25) . Also, surfactant-stripped naphthalocyanines developed by Zhang et al. were used for multimodal (ultrasound, photoacoustic, and PET) functional imaging in the gastrointestinal tract of a mouse (26) .
Molecular Targeting Approach for PAI
Passive targeting relevant to oncology is based on size-dependent accumulation in solid tumors because of enhanced permeability and retention caused by leaky vasculature and poor lymphatic drainage in tumors. For active targeting, identifying the biomarkers that should be overexpressed on the target is required. As a targeting ligand, several structures are used, including small molecules, peptide/ adhirons, Affibody, aptamer, and antibody/protein (27) . Some efforts were made to use these targeting ligands to achieve a molecular PAI.
Zhang et al. engineered a cystineknot peptide, R 0 1, labeled with Atto740 dye and evaluated it using a v b 6 -positive (A431) and a v b 6 -negative (293T) tumors in mice (28) . Significant photoacoustic signal enhancement was found in A431 tumors over 4 h after injection (Figs. 4A-4C) . Levi et al. showed that their developed peptide, AA3G-740, successfully binds to gastrin-releasing peptide receptor in mouse prostate cancer, improving photoacoustic signal almost 2-fold compared with the control agent (29). Sano et al. suggested an antiepidermal growth factor receptor monoclonal antibody labeled with indocyanine green to target cancer associated with epidermal growth factor receptor. The dye highly accumulated on epidermal growth factor receptor-positive (A431 and MDA-MB-468) compared with -negative tumors (T47D) (30) . These technologies to simultaneously image both vascular networks by endogenous contrast and molecular features by exogenous contrast will enable molecular PAI for diagnosis and photoacoustic guided biopsy.
Laser-Activated Therapy with Guidance of PAI
In recent years, PAI was used for guiding laser-activated therapy, photothermal therapy, and photodynamic therapy in preclinical research. Functional and molecular features of tissue shown by PAI, such as vasculature, hemodynamics, functional connectivity, melanoma, and temperature, have been used for monitoring treatment efficacy (31) . In addition, PAI has potential for monitoring drug distribution and concentration (31) . Photothermal therapy is localized thermal ablation using photothermal-conversion agents. Because the laser source can be shared, the synergetic ability for concurrent imaging and therapy has potential to monitor the accumulation of agents on-site during photothermal therapy. Zhang et al. successfully demonstrated treatment of a mouse tumor using terrylenediimide-based agents under PAI guidance (32) . The agents showed photothermal conversion efficiency of up to 40%, with peak absorption at 640-690 nm, which is well suited for both photothermal therapy and PAI. Muhanna et al. showed photothermal therapy with porphysomes, organic nanoparticles developed for fluorescence and photoacoustic dualmodality imaging (33) . Porphysomeenabled photothermal therapy allowed for PAI-monitored target-specific ablation of buccal and tongue carcinomas in hamster, and its progress was monitored by PAI (Figs. 4D and 4E) .
Photosensitizers for photodynamic therapy require oxygen to generate toxic singlet oxygen that kills the target cells. Near-infrared light is desired for laser activation at sufficient depths while also allowing for deep PAI. Yu et al. demonstrated PAI with a clinical photosensitizer, verteporfin, on a mouse tumor (34). Ho et al. evaluated the photoacoustic efficacy of 5 different photosensitizers (35) . Zinc phthalocyanine exhibited the most efficient photoacoustic response, and in vivo feasibility was shown using a mouse tumor model.
CONCLUSION AND FUTURE DIRECTION
PAI with advanced multifunctional theranostic agents has great potential as a noninvasive and nonionization biomedical molecular imaging and treatment tool. In addition to advanced molecular probes, clinical acceptance will increase with the advent of faster, more compact, affordable, and clinically friendly systems. One big barrier is the laser. A Q-switched solid-state laser for a typical PAI system is bulky and costly, and the wavelength-tuning speed on the optical-parametric-oscillator is too slow to achieve real-time multispectral PAI. Recently, Schwarz et al. (36) introduced a PAI system with a high repetition rate (100 Hz) and a fast wavelength-tuning speed (10 ms). In addition, there have been efforts to develop affordable PAI systems, such as replacing the bulky solidstate lasers with diode lasers or light-emitting diodes and integrating the light source and the detector into a handheld probe (37, 38) . In efforts to make PAI more suitable for freehand scanning in a clinical environment, a concavemirror-shaped device attached to the ultrasound probe was proposed to not only protect an operator and a patient from unwanted exposure to the reflected laser light but also improve the signal-to-noise-ratio for deep tissue imaging (34) . Exogenous photoacoustic contrast agents also should be further evaluated under biologically relevant conditions to assess bioeffects and improve binding or treatment efficiency in situ. All these approaches will bring PAI closer to clinical application. Continued efforts to develop clinically friendly systems and novel multifunctional photoacoustic contrast agents and to validate them in human subjects will accelerate the clinical introduction of photoacoustic technologies.
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